<DOC>
	<DOCNO>NCT01296477</DOCNO>
	<brief_summary>There mount body evidence suggest large disparity development actual implementation guideline-driven asthma care primary specialty care practice . To address disparity , American Academy Allergy , Asthma &amp; Immunology ( AAAAI ) develop unique , comprehensive easy-to-use Web-based tool clinician treat asthma patient call `` Asthma Specialist Tool Help Manage Asthma Improve Quality '' ( Asthma-IQ ) . This study examine whether use Asthma IQ primary care tool improve asthma care asthma outcome use randomized trial Asthma IQ system versus usual asthma care primary care set 1 year . At end 1 year , patient manage use Asthma-IQ tool additional year determine patient manage usual care first year improve manage conjunction Asthma-IQ . The primary endpoint determine use Asthma IQ tool improve asthma patient outcomes quarterly assessment Asthma Control Test ( ACT ) score via automate / electronic patient survey . The secondary endpoint asthma exacerbation number exploratory endpoint define clinical utility primary care version Asthma-IQ . This study involve recruit approximately 20 family medicine office approximately 20 patient , conduct randomize , multiple time point intervention trial . The necessary total recruit patient sample size 200 per group . The result study help determine utility Web-based tool help manage chronic disease asthma .</brief_summary>
	<brief_title>To Evaluate Use ASTHMA IQ Primary Care Setting</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>1 . Male female patient , age 12 65 year time screening ; 2 . Written inform consent obtain patient prior begin study procedure ; 3 . Documented clinical history chronic persistent asthma require controller therapy ; 4 . Able complete study period , include followup period , approximately 2 year ; 5 . Willing forego form experimental treatment study procedure study 30 day followup period complete . 1 . History disease , evidence current disease ( asthma ) , find upon physical examination , laboratory abnormality , , opinion investigator , may compromise safety patient study confound analysis study ; 2 . Lung disease asthma ( e.g. , chronic obstructive pulmonary disease , cystic fibrosis ) ; 3 . Any disease illness , asthma , likely require use systemic corticosteroid study period ; 4 . Current acute illness evidence significant active infection , fever ≥ 38.0°C ( 100.5°F ) within 4 week enrollment ; 5 . Receipt investigational drug therapy within 30 day biologic ( ) within 5 halflives prior screen , except omalizumab asthma ; 6 . Pregnancy enrollment ; 7 . Breastfeeding lactating female ; 8 . Elective major surgery plan screen study completion ; 9 . History cancer basal cell carcinoma skin cervical carcinomainsitu treat apparent success curative therapy 1 year prior enrollment ; 10 . History primary immunodeficiency ; 11 . History within past year excessive alcohol intake drug addiction . 12 . History tobacco use 10 pack year ; 13 . Plans move study site area duration study . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>ASTHMA IQ tool</keyword>
	<keyword>Asthma Control Test ( ACT )</keyword>
	<keyword>EPR-3 Guidelines , Exacerbations</keyword>
</DOC>